ILLUMINA NASDAQILMN STOCK QUOTE

https://www.illumina.com/

LATEST NEWS FROM ILLUMINA

Illumina to Announce Fourth Quarter & Full Year 2021 Financial Results on Thursday, February 10, 2022

Illumina collaborates with Nashville Biosciences to accelerate medicines development

Illumina Partners with Agendia to Expand Genomic Testing in Breast Cancer Care

Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care

Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership

Illumina delivers 2021 results ahead of expectations, strong 2022 guidance and deep pipeline of long-term growth opportunities at 2022 J.P. Morgan Healthcare Conference

Knight Cancer Institute at Oregon Health & Science University to Offer the Galleri® Multi-Cancer Early Detection Test

GRAIL and Premier’s PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test

Illumina Enters Co-Development Partnership with SomaLogic

Illumina and Syapse Partner on Research to Evaluate Large Panel Biomarker Testing Patterns Across US Community Oncology Practices

Illumina To Webcast Upcoming Investor Conference

Gretel and Illumina Partner to Develop Synthetic Data for Genomic Research

Illumina Supports Norway's Pioneering Precision Medicine Study

GRAIL Announces Partnership with Alignment Health Plan as First Medicare Advantage Plan to Offer Galleri® Multi-Cancer Early Detection Blood Test

Illumina and Sequoia Capital China Select First Startups to join Genomics Incubator in China

Illumina and Genetic Alliance Launch $120 Million Global Initiative to Increase Equity and Improve Outcomes for Families Impacted by Genetic Disease

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2021

Illumina Supports Canada's Nationwide COVID-19 Genome Sequencing Initiative

Illumina Supports Israel's National Program to Accelerate Diagnoses of Critically-Ill Newborns with Suspected Genetic Disease

Illumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021

Illumina Appoints Bob Ragusa as Chief Executive Officer of GRAIL

Illumina to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021

Illumina Expands Presence in Latin America

Randomized trial demonstrates whole-genome sequencing leads to precision care for critically ill infants

Dante Labs Announces Appointment of Global Legal Expert Rachel Haverfield as General Counsel to its Expanding Leadership Team

Illumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle

Dante Labs Announces Expansion of its Finance Team with the Appointment of Andre Nel as Chief Financial Officer, Dalila Rahmani as Chief Accounting Officer, Laura D’Angelo as VP Investor Relations and Omar Elbakshish as Senior Director

Illumina Commits to Net Zero Global Greenhouse Gas Emissions by 2050

Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations

Illumina To Webcast Upcoming Investor Conference

Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2021

Illumina Donates $1 Million in Sequencing Capabilities to Mumbai to Support Sequencing-Based COVID-19 Surveillance in India

Illumina to Webcast Upcoming Investor Conference

Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase

Dante Labs appoints Illumina acclaimed COO Bob Ragusa as Board Member to support the execution of its global integrated precision medicine strategy

Illumina to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021

DNA Data Storage Alliance Publishes First White Paper, Launches Website

Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis

Illumina To Webcast Upcoming Investor Conference

Illumina Appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of Research and Product Development

Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives

Illumina To Webcast Upcoming Investor Conference

Illumina Files Action for Annulment of European Commission’s Decision Asserting Jurisdiction to Review GRAIL Acquisition

Illumina to Donate US $60 Million in Sequencing Capabilities to Establish a Global Pathogen Genomics Initiative

Illumina Reports Financial Results for First Quarter of Fiscal Year 2021

Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic

Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors

Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021

Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

Illumina Announces Board Changes

Iridia Raises $24 Million in Series B Funding

Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia

Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2020

Illumina to Webcast Upcoming Investor Conference Presentations

Illumina Accelerator Invests in Nine Genomics Startups for Second Global Cycle

Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium

Illumina and Sequoia Capital China Partner to Launch Genomics Incubator in China

Illumina to Announce Fourth Quarter & Full Year 2020 Financial Results on Thursday, February 11, 2021